BNO
Click for more information
0.00% 1.0¢ bionomics limited

The SAD treatman alone has a potential of peak revenues of...

  1. jogibaer
    50 Posts.
    lightbulb Created with Sketch. 2
    clock Created with Sketch.
    16/10/22
    20:28
    Post #: 64224658
    The SAD treatman alone has a potential of peak revenues of around 1.6 billion usd p.a. in the USA alone. The market introduction is forecasted after potential phase 3 in 2026. There are no side effects for this treatment. Cash reach for the company is forecasted after the both readouts. Very interesting. Maybe an outlicensing deal after sucessful phase 2 or a takeover
    BNO Price at posting: 6.6¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

3DP Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios
right-arrow Created with Sketch.
SVL Silver Mines models five new calderas close to 396Moz Bowdens deposit
right-arrow Created with Sketch.
NEWS Tenant turnover: Reducing costs and revenue-loss
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
ABY Adore Beauty buys up wellness brand iKOU for $25M cash
right-arrow Created with Sketch.
LYC Lynas eyes first dysprosium, terbium HREE production in CY25
right-arrow Created with Sketch.
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.